Thermo Fisher Scientific Inc. $TMO Shares Acquired by Swedbank AB

Key Points

• Swedbank AB increased its holdings in Thermo Fisher Scientific by 11.3% in the 1st quarter, owning a total of 1,583,776 shares, worth approximately $788 million.
• Thermo Fisher Scientific's recent quarterly earnings showed an EPS of $5.36, beating estimates, with a revenue of $10.86 billion, representing a 2.9% year-over-year increase.
• The company announced a quarterly dividend of $0.43 per share, leading to an annualized dividend of $1.72 and a yield of 0.4%.

Swedbank AB grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,583,776 shares of the medical research company's stock after acquiring an additional 160,621 shares during the quarter. Thermo Fisher Scientific accounts for approximately 1.0% of Swedbank AB's holdings, making the stock its 17th largest holding. Swedbank AB owned 0.42% of Thermo Fisher Scientific worth $788,087,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of TMO. Brighton Jones LLC raised its stake in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its holdings in Thermo Fisher Scientific by 0.3% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock valued at $79,677,000 after purchasing an additional 461 shares during the last quarter. Nomura Holdings Inc. boosted its holdings in Thermo Fisher Scientific by 179.1% in the fourth quarter. Nomura Holdings Inc. now owns 15,427 shares of the medical research company's stock valued at $8,026,000 after purchasing an additional 9,899 shares during the last quarter. Finally, MainStreet Investment Advisors LLC purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at $233,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 3.1%

Shares of TMO opened at $491.29 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77. The stock's 50 day moving average is $465.84 and its two-hundred day moving average is $452.06. The firm has a market cap of $185.52 billion, a P/E ratio of 28.41, a PEG ratio of 2.54 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the company earned $5.37 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent research reports. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $490.00 to $550.00 in a report on Thursday. Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Robert W. Baird lifted their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Finally, Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research report on Friday, July 11th. Seventeen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $592.24.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.